Show simple item record

dc.contributor.authorO'Connor, Rachael
dc.contributor.authorBaines, Simon D.
dc.contributor.authorFreeman, Jane
dc.contributor.authorWilcox, Mark H.
dc.identifier.citationO'Connor , R , Baines , S D , Freeman , J & Wilcox , M H 2008 , ' In vitro susceptibility of genotypically distinct and clonal Clostridium difficile strains to oritavancin ' , Journal of Antimicrobial Chemotherapy , vol. 62 , no. 4 , pp. 762-5 .
dc.identifier.otherPURE: 1352019
dc.identifier.otherPURE UUID: 81a8c8ae-fd3d-41f3-bad7-365d2548ab3d
dc.identifier.otherPubMed: 18606787
dc.identifier.otherScopus: 52949105801
dc.description.abstractClostridium difficile infection is a nosocomial disease of increasing importance. First-line treatment is limited to metronidazole or vancomycin. Oritavancin is a lipoglycopeptide with activity against Gram-positive bacteria, including drug-resistant pathogens. MICs of oritavancin, metronidazole and vancomycin for genotypically distinct C. difficile strains, including epidemic C. difficile PCR ribotypes 001 and 027, were determined by agar incorporation and broth macrodilution methods. In agar incorporation methods, the impact of supplements on oritavancin MICs was tested to address oritavancin binding to surfaces.en
dc.relation.ispartofJournal of Antimicrobial Chemotherapy
dc.titleIn vitro susceptibility of genotypically distinct and clonal Clostridium difficile strains to oritavancinen
dc.contributor.institutionDepartment of Human and Environmental Sciences
dc.contributor.institutionSchool of Life and Medical Sciences
dc.contributor.institutionHealth & Human Sciences Research Institute
dc.contributor.institutionMicrobiology and Biotechnology
dc.contributor.institutionGeography, Environment and Agriculture
dc.contributor.institutionAgriculture, Veterinary and Food Sciences
dc.description.statusPeer reviewed
rioxxterms.typeJournal Article/Review

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record